Impact of apixaban treatment discontinuation on the risk of hospitalization among patients with nonvalvular atrial fibrillation and COVID-19-Reference-Cited by-同舟云学术

Impact of apixaban treatment discontinuation on the risk of hospitalization among patients with nonvalvular atrial fibrillation and COVID-19

Published:2022-08-30 Issue:11 Volume:38 Page:1891-1896
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Deitelzweig Steven¹²,Zhu Julia³,Jiang Jenny³,Luo Xuemei⁴,Keshishian Allison⁵,Ferri Mauricio³,Rosenblatt Lisa³,Schuler Patricia³,Gutierrez Cynthia⁵,Dhamane Amol D.³

Affiliation:

1. Department of Hospital Medicine, Ochsner Clinic Foundation, New Orleans, LA, USA

2. Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, LA, USA

3. Bristol Myers Squibb, Lawrenceville, NJ, USA

4. Pfizer, New York, NY, USA

5. STATinMED LLC, Dallas, TX, USA

Funder

Pfizer

Bristol Myers Squibb and Pfizer

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2022.2112871

Reference26 articles.

1. COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies

2. Management of Atrial Fibrillation in COVID-19 Pandemic

3. Guidance on Short‐Term Management of Atrial Fibrillation in Coronavirus Disease 2019

4. Atrial fibrillation and the risk of 30‐day incident thromboembolic events, and mortality in adults ≥ 50 years with COVID‐19

5. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ecofriendly bioanalytical validated RP-HPLC method for simultaneous determination of COVID-19 co-prescribed drugs employing quality by design and green chemistry;Microchemical Journal;2024-05

2. Clinical outcomes of oral anticoagulant discontinuation in atrial fibrillation: a systematic review and meta-analysis;Expert Review of Clinical Pharmacology;2023-06-18

3. Impact of atrial fibrillation and anticoagulation on the risk of death, thromboembolic disease and bleeding in patients with COVID-19: the ACO-VID Registry;Current Medical Research and Opinion;2023-05-15

4. Prognostic Significance of the Coagulation and Complement Systems in Critical COVID-19 Infection;Prague Medical Report;2023